











From 1983 to 2016:

11020 deaths

56001 cases of HIV

- 21614 cases of AIDS (39%)


# HIV INFECTION AND AIDS IN PORTUGAL 35 YEARS LATER

Caixeiro, M.<sup>1</sup>; Graça, L.<sup>2</sup>; Guedes, M.<sup>2</sup>; Ruas, R.<sup>2</sup>; Soeiro, C.<sup>3</sup>

<sup>1</sup>Hospital Prof. Doutor Fernando Fonseca, Amadora; <sup>2</sup> Centro Hospitalar de São João, Porto; <sup>3</sup> Centro Hospitalar do Porto, Porto

### Evolution of New HIV Infections 1,2


✓ In 2016, an estimated total of 38959 people were living with HIV in Portugal;






#### ✓ In 2017









Sexual transmission

#### **CD4 Count**




- ✓ In 2017, PrEP was approved by the government and is available since February 2018;
- ✓ In 2018 it's the 25<sup>th</sup> anniversary of the "Syringe Exchange program" that was responsible for the decline in the rates of HIV infection among IV drug users.


## AIDS and associated mortality 1,2




#### Most common AIDS defining illnesses per year of diagnosis of AIDS



- ✓ The incidence of AIDS has been declining but is still one of the highest in Western Europe. Tuberculosis is the most prevalent cumulative AIDS defining illness, but in the last decade, Pneumocystis pneumonia has been the most frequently reported.
- ✓ The mortality has decreased dramatically and most patients survive over a decade after the diagnosis of HIV infection.



### UNAIDS 90-90-90 <sup>1</sup>




**WUNAIDS** 

2 out of 3 targets achieved in 2016


## HIV-2 INFECTION 3,4

- Discovered in 1986;
- Around I-2 million people infected in the world, mostly in West Africa;
- Less pathogenic than HIV-I;
- Longer asymptomatic stage with slower decline in T CD4<sup>+</sup> cell count;
- Lower viral load in the plasma and lower transmission rate;
- Deterioration of T CD4<sup>+</sup> count can occur with undetectable viremia;
- Similar opportunist disease with late stage HIV-2;
- Urgent need of point-of-care testing and viral load monitoring in resource-limited settings;
- Intrinsic resistance to treatment with NNRTIs and enfuvirtide. <sup>3</sup>





88.6% Heterosexual transmission



5.9% Other routes (mother-child, MSM, IDU, haemophiliac)


✓ Median CD4<sup>+</sup> count (2013-2017) 427cells/mm<sup>3</sup>

Median age at diagnosis 56 years old (minimum 7 yo; maximum 87 yo)

34.4% Portuguese56.4% Sub-Saharan Africa

75.7%

Asymptomatic at diagnosis



√69.2% live in the Lisbon urban area

16.2% Cape Verde

76.3% Guinea-Bissau

90-90-90 for HIV-2?